Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L, Pasco S, Hornebeck W, Maquart FX, Monboisse JC. Ramont L, et al. Exp Cell Res. 2003 Nov 15;291(1):1-10. doi: 10.1016/s0014-4827(03)00336-7. Exp Cell Res. 2003. PMID: 14597403
[Biological effects of collagen I and IV peptides].
Pasco S, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Among authors: ramont l. J Soc Biol. 2003;197(1):31-9. J Soc Biol. 2003. PMID: 12868264 Review. French.
The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, Maquart FX, Alix AJ, Monboisse JC. Floquet N, et al. Among authors: ramont l. J Biol Chem. 2004 Jan 16;279(3):2091-100. doi: 10.1074/jbc.M307736200. Epub 2003 Oct 28. J Biol Chem. 2004. PMID: 14583633
An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion.
Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. Maquart FX, et al. Among authors: ramont l. Crit Rev Oncol Hematol. 2004 Mar;49(3):199-202. doi: 10.1016/j.critrevonc.2003.06.007. Crit Rev Oncol Hematol. 2004. PMID: 15036260 Review.
Control of melanoma progression by various matrikines from basement membrane macromolecules.
Pasco S, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Among authors: ramont l. Crit Rev Oncol Hematol. 2004 Mar;49(3):221-33. doi: 10.1016/j.critrevonc.2003.09.006. Crit Rev Oncol Hematol. 2004. PMID: 15036262 Review.
The small leucine-rich proteoglycan lumican inhibits melanoma progression.
Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX, Wegrowski Y. Vuillermoz B, et al. Among authors: ramont l. Exp Cell Res. 2004 Jun 10;296(2):294-306. doi: 10.1016/j.yexcr.2004.02.005. Exp Cell Res. 2004. PMID: 15149859
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, Monboisse JC. Pasco S, et al. Among authors: ramont l. Exp Cell Res. 2004 Dec 10;301(2):251-65. doi: 10.1016/j.yexcr.2004.07.036. Exp Cell Res. 2004. PMID: 15530861
Control of melanoma cell invasion by type IV collagen.
Pasco S, Brassart B, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Among authors: ramont l. Cancer Detect Prev. 2005;29(3):260-6. doi: 10.1016/j.cdp.2004.09.003. Epub 2004 Nov 23. Cancer Detect Prev. 2005. PMID: 15936594 Review.
Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin.
Thevenard J, Floquet N, Ramont L, Prost E, Nuzillard JM, Dauchez M, Yezid H, Alix AJ, Maquart FX, Monboisse JC, Brassart-Pasco S. Thevenard J, et al. Among authors: ramont l. Chem Biol. 2006 Dec;13(12):1307-15. doi: 10.1016/j.chembiol.2006.10.007. Chem Biol. 2006. PMID: 17185226
The NC1 domain of type XIX collagen inhibits in vivo melanoma growth.
Ramont L, Brassart-Pasco S, Thevenard J, Deshorgue A, Venteo L, Laronze JY, Pluot M, Monboisse JC, Maquart FX. Ramont L, et al. Mol Cancer Ther. 2007 Feb;6(2):506-14. doi: 10.1158/1535-7163.MCT-06-0207. Mol Cancer Ther. 2007. PMID: 17308049
52 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback